Home > Dermatology > AAD 2022 > Posters > Dermatology diseases need the highest doses of biologics

Dermatology diseases need the highest doses of biologics

Presented By
Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA
Presented by
Charlotte Greif
Conference
AAD 2022
When comparing different biologic agents and their regimens for various inflammatory conditions, it appeared that patients with dermatologic diseases require the highest doses for loading and maintenance. For the treatment of psoriasis, the use of loading doses provided short-term but no long-term benefits. Reasons for prescribing loading doses in biologic treatment are various, including aiming for a faster clinical response and to quickly achieve therapeutic drug levels and disease control at the beginning of treatment [1,2]. Dr Charlotte Greif (Beth Israel Deaconess Medical Center, MA, USA) and her colleagues reviewed 254 studies that compared biologic treatment for psoriasis and other inflammatory diseases, such as rheumatic diseases or inflammatory bowel disease, concerning the advantages of loading doses [1]. Only 5 of those studies included head-to-head assessment of loading doses, with direct comparison data for adalimumab, etanercept, and secukin...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on